Oxygap 2: Comparison of Pulse Oximetry (SpO2) With Different Oximeters and Arterial Saturation (SaO2): Oxygap2 Study

Sponsor
Laval University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06102499
Collaborator
(none)
200
3
15
66.7
4.4

Study Details

Study Description

Brief Summary

The oximeter is used to monitor intensive care patients undergoing oxygen therapy. It indicates pulsed oxygen saturation (SpO2), a reflection of arterial oxygen saturation (SaO2) which enables detection of hypoxemia and hyperoxia, both deleterious state. Current SpO2 recommendations aim to reduce both risk of hypoxemia and hyperoxia. SpO2 is considered the 5th vital sign.

Current recommendations for SpO2 targets do not consider the variability of oximeters used in clinical practice. This variability and lack of specification represent an obstacle to an optimal practice of oxygen therapy.

Thus, this study aims to compare the SpO2 values of different oximeters (General Electric-GE, Medtronic, Masimo and Nonin) used in clinical practice with the SaO2 reference value obtained by an arterial gas in order to specify the precision and the systematic biases of the oximeters studied. This data will also make it possible to refine the recommendations concerning optimal oxygenation

Condition or Disease Intervention/Treatment Phase
  • Device: SpO2 and SaO2 comparison

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Comparison of Pulse Oximetry (SpO2) With Different Oximeters and Arterial Saturation (SaO2): Oxygap2 Study
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Jun 30, 2024
Anticipated Study Completion Date :
Dec 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Pediatric population

Pediatric population < 18 years old (estimated 100 patients)

Device: SpO2 and SaO2 comparison
Several pulse oximeter will be place on patient find few minutes before arterial blood gases. During an arterial blood sample, all SpO2 will be recorded

Adult population

Adult population >or= 18 years old (estimated 100 patients)

Device: SpO2 and SaO2 comparison
Several pulse oximeter will be place on patient find few minutes before arterial blood gases. During an arterial blood sample, all SpO2 will be recorded

Outcome Measures

Primary Outcome Measures

  1. Difference between GE oximeter SpO2 value and the SaO2 value on arterial blood gases [During procedure (arterial blood gas sample collection)]

    Difference between GE oximeter SpO2 and the SaO2 value

  2. Difference between Nellcor oximeter SpO2 value and the SaO2 value on arterial blood gases [During procedure (arterial blood gassample collection)]

    Difference between Nellcor oximeter SpO2 and the SaO2 value

  3. Difference between Masimo oximeter SpO2 value and the SaO2 value on arterial blood gases [During procedure (arterial blood gas sample collection)]

    Difference between Masimo oximeter SpO2 and the SaO2 value

  4. Difference between Nonin oximeter SpO2 value and the SaO2 value on arterial blood gases [During procedure (arterial blood gas sample collection)]

    Difference between Nonin oximeter SpO2 and the SaO2 value

Secondary Outcome Measures

  1. Overestimation and underestimation of SaO2 [During procedure (arterial blood gas sample collection)]

    Percent of pairs with overestimation and underestimation of SaO2 for each oximeter.

  2. Hypoxemia detection [During procedure (arterial blood gas sample collection)]

    Ability to detect hypoxemia (SpO2 below 90% and PaO2 < 60 mmHg)

Other Outcome Measures

  1. Hyperoxemia detection [During procedure (arterial blood gas sample collection)]

    Ability to detect hyperoxemia (SpO2 above 95% and PaO2 > 100 mmHg)

  2. Gaps between the different oximeters [During procedure (arterial blood gas sample collection)]

    Average of the SpO2 value gaps between the different oximeters tested

Eligibility Criteria

Criteria

Ages Eligible for Study:
0 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Adult population

Inclusion Criteria:
  • ≥ 18 years old (adult population) -

  • Patients admitted to the Intensive Care Unit

  • Artery catheter already installed

Pediatric population

  • Below 18 years old

  • Patients admitted to the Intensive Care Unit

  • Artery catheter already installed

Exclusion Criteria:
  • No or poor signal with the usual pulse oximeter/based on clinician judgment

  • High dose of vasopressors or inotropes (epinephrine or norepinephrine ˃ 1mcg/kg/min), shock state (lactates above 3 mmoles/L)

  • Pigmented nails or nail polish

  • Methemoglobinemia history

  • Hemoglobin below 80 g/L

  • Patient in isolation (multi-resistant bacteria, C-Difficile, SARS-COV-2…)

  • Prone position, Extra Corporel Membrane Oxygenator

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHUM Montréal Quebec Canada H2X0A9
2 CHU Ste-Justine Montréal Quebec Canada H3T 1C5
3 Institut Universitaire de Cardiologie et de Pneumologie de Québec Quebec Canada G1V 4G5

Sponsors and Collaborators

  • Laval University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
François Lellouche, Principal Investigator, Laval University
ClinicalTrials.gov Identifier:
NCT06102499
Other Study ID Numbers:
  • 22373
First Posted:
Oct 26, 2023
Last Update Posted:
Oct 26, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 26, 2023